# A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

> **NCT05740956** · PHASE1 · RECRUITING · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 318 (estimated)

## Conditions studied

- Ovarian Cancer
- Breast Cancer
- Pancreatic Cancer
- Prostatic Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** HS-10502

## Key facts

- **NCT ID:** NCT05740956
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-09
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 318 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740956, "A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05740956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*